1.Baldan J#*, Camacho-Roda J#, Ballester M#, Hoj K, Kurilla A, Maurer H, Arcila-Barrera S, Lin X, Pan Z, Castro J, Guiliani A, Rift C, Hasselby J, Bouwens L, Lefebvre V, David C, Parnas O, Kathleen E, Janine R, Arnes Luis* (2024) Resolution of Acinar Dedifferentiation Regulates Tissue Remodeling in Pancreatic Injury and Cancer Initiation. Gastroenterology. (#equal contribution)
2.Liu X#, Liu X#, Du Y#, Zou D, Tian C, Li Y, Lan X, David C, Sun Q, Chen M*(2023) Aberrant accumulation of Kras-dependent enhancer RNAs and PROMPTs during tumor progression renders cancer cells susceptible to PAF1 depletion. Cell Reports 42,112979.
3.Zhuo M*, Mao J, David C* (2023) Protocol to package and concentrate adeno-associated virus serotype 8 for use in autochthonous mouse models of pancreatic cancer. STAR protocols 4 (1), 102108.
4.Liu X#, Guo Z#, Han J#, Peng B, Zhang B, Li H, Hu X, David C, Chen M*(2022) The PAF1 complex promotes 3’ processing of pervasive transcripts. Cell Reports 38,110519.
5.Meng J, Zhao S, Tao Y, Zhang T, Wang X, Zhang Y, Sun K, Yuan M, Chen J, Wei Y, Lan X, Chen M*, David C, Chang Z, Guo X, Pan D, Chen M, Shao Z*, Kang Y*, Zheng H* (2022) Tumor-derived Jagged1 promotes cancer progression through immune evasion. Cell Reports38, 110492.
6.Li Y#, He Y#, Peng J#, Li Z, Zhang B, Ma J, Zhuo M, Zou D, Liu X, Liu X, Wang W, Huang D, Xu M, Wang J, Deng H, Xue J, Xie W, Lan X, Chen M, Zhao Y*, Wu W* and David C* (2021) Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer. Nature Cancer 2:49-65. (#equal contribution)
7.Su J , Morgani S, David C, Wang Q ,Er E, Huang Y, Basnet H , Zou Y, Shu W,Soni R, Hendrickson R, Hadjantonakis A, Massague J* (2020) TGF-β orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1.Nature 577(7791)566-571.
8.Huang Y, Hu J, Chen, F, Lecomte N, Basnet H, David C, Witkin M, Allen P, Leach S, Hollmann T, Iacobuzio-Donahue C, Massague J* (2020) ID1 mediates escape from TGFβ tumor suppression in pancreatic cancer. Cancer discovery 10 (1), 142-157.
9.David C#, Massague J#* (2018) Contextual determinants of TGFβ action in development, immunity and cancer. Nature reviews Molecular cell biology 19 (7):419-435.
10.David C, Huang Y, Chen M, Su J, Zou Y, Bardeesy N, Iacobuzio-Donahue CA, Massague J* (2016) TGF-β Tumor Suppression Through A Lethal EMT. Cell 164:1015-30.
11.Chen M, David C, Manley J* (2012) Concentration-dependent control of pyruvate kinase M mutually exclusive splicing by hnRNP proteins. Nat Struct Mol Biol 19:346-54.
12.David C, Manley J* (2011) The RNA polymerase C-terminal domain: a new role in spliceosome assembly. Transcription 2 (5), 221-225.
13.Kashima T, Rao N, David C, Manley J* (2011)The RNA polymerase II C-terminal domain promotes splicing activation through recruitment of a U2AF65–Prp19 complex. Genes & development 25 (9):972-983.
14.Chen M, David C, Manley J* (2010) Tumor metabolism: hnRNP proteins get in on the act. Cell Cycle 9: 1863-1864.
15.David C#, Chen M#, Assanah M, Canoll P, Manley J* (2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463: 364-8. (#equal contribution)
16.David C, Manley J* (2008) The search for alternative splicing regulators: new approaches offer a path to a splicing code. Genes & development 22 (3), 279-285.
17.Kashima T*, Rao N, David C, Manley J* (2007) hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. Human molecular genetics16(24):3149-3159.